NCT06916104

Brief Summary

The aim of this study is to take stock of the situation of adult patients with severe asthma on biotherapy, followed up at Poitiers University Hospital, and in particular to increase our knowledge of factors predictive of response to biotherapy. The main aim is to improve the management of adult severe asthma patients treated with biotherapy, according to their allergic status.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2024

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2024

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

March 31, 2025

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

April 8, 2025

Completed
Last Updated

April 8, 2025

Status Verified

March 1, 2025

Enrollment Period

1.1 years

First QC Date

March 31, 2025

Last Update Submit

March 31, 2025

Conditions

Severe AsthmaBiotherapyRespiratory Allergy

Outcome Measures

Primary Outcomes (1)

  • Find out whether a positive respiratory allergy test influences the efficacy of one or more biotherapies

    1 year

Secondary Outcomes (2)

  • analyze the allergological workup, particularly with regard to common pneumallergens

    1 year

  • look at the response to the biotherapy used

    1 year

Study Arms (1)

adult patients with severe asthma on biotherapy

Other: search for respiratory allergies

Interventions

search for respiratory allergiesOTHER

analyses in terms of biotherapy and respiratory allergy

adult patients with severe asthma on biotherapy

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

severe asthma patients on dual therapy at POITIERS University Hospital

You may qualify if:

  • Severe asthma patient on biotherapy
  • Age \> or = 18 years
  • Follow-up at Poitiers University Hospital

You may not qualify if:

  • Absence of allergological assessment
  • Patient's refusal to participate in study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chu Poitiers

Poitiers, 86000, France

Location

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 31, 2025

First Posted

April 8, 2025

Study Start

March 1, 2024

Primary Completion

March 31, 2025

Study Completion

March 31, 2025

Last Updated

April 8, 2025

Record last verified: 2025-03

Locations

FR(1)